Press

American Medical Association Releases Language of First New Current Procedural Terminology Code for Psychedelic Therapies

Jul 11 • 4 min read

COMPASS Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, today announced that the American Medical Association has released the language of its new Current Procedural Terminology (CPT®) III code for Continuous In-Person Monitoring and Intervention During Psychedelic Medication Therapy. The code will go into effect and will be…

The Healing Company Uplists to the OTCQB Venture Market and Secures New Strategic Investors

Jul 10 • 4 min read

The Healing Company (OTCQB: HLCO), today announced that it has successfully uplisted from the OTC Pink Market to the OTCQB Venture Market (“OTCQB”) and will continue trading under the symbol “HLCO”. Additionally, The Healing Company announced it had secured up to $7 million in new investment from strategic partners including the investment office of the Burman…

Numinus to Present at the Small Cap Growth Virtual Investor Conference on July 13, 2023

Jul 10 • 2 min read

Numinus Wellness Inc. (TSX: NUMI / OTCQX: NUMIF) – a mental health care company advancing innovative treatments and safe, evidence-based psychedelic-assisted therapies, today announced that Payton Nyquvest, Founder and CEO, will present live at the Small Cap Growth 50 Virtual Investor Conference, hosted by VirtualInvestorConferences.com, on July 13, 2023. DATE: July 13, 2023TIME: 2:30 pm ET / 11:30 am PTLINK: https://bit.ly/43mPSpB This will…

PharmAla Biotech Holdings Inc. – Cortexa Makes First Drug Order for Australian Commercial Market

Jul 7 • 2 min read

PharmAla Biotech Holdings Inc. (CSE: MDMA / OTC: PMBHF), a biotechnology company focused on the research, development, and manufacturing of novel MDXX class molecules (including MDMA), is pleased to announce that Cortexa, its Joint Venture with Australian company Vitura Health (ASX: VIT) has executed its first purchase order for PharmAla’s GMP LaNeo MDMA, in both finished capsule…

Mydecine Reports its Special Meeting Results

Jul 7 • 3 min read

Mydecine Innovations Group Inc. (NEO:MYCO / OTC:MYCOF / FSE:0NFA), a biotechnology company engineering the next wave of innovative medications and treatment protocols to directly address mental health with a particular emphasis on addiction and PTSD, is pleased to announce the results of voting at its special meeting of shareholders which was held on Tuesday, July…

Pages: 123456789101112131415161718192021222324252627282930313233343536373839404142434445464748495051525354555657585960616263646566676869707172737475767778798081828384858687888990919293949596979899100101102103104105106107108109110111112113114115116117118119120121122123124125126127128129130131132133134135136137138139140141142143144145146147148149150151152153154155156157158159160161162163164165166167168169170171172173174175176177178179180181182183184185186187188189190191192193194195196197198199200201202203204205206207208209210211212213214215216217218219220221222223224225226227228229230231232233234235236237238239240241242243244245246247248249250251252253254255256257258259260261262263264265266267268269270271272273274275276277278279280281282283284285286287288289290291292293294295296297298299300301302303304305306307308309310311312313314315316317318319320321322323324325326327328329330331332333334335336337338339340341342343344345346347348349350351352353354355356357358359360361362363364365366367368369370371372373374375376377378379380381382383384385386387388389390391392393394395396397398399400401402403404405406407408409410411412413414415416417418419420421422423424425426427428429430431432433434435